Ticker
ADAG

Price
1.84
Stock movement down
-0.05 (-2.65%)
Company name
Adagene Inc
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Biotechnology
Markedsværdi
79.90M
Ent værdi
-22.26M
Pris/omsætning
-
Pris/bog
0.71
Udbytte afkast
-
Udbyttevækst
-
Vekst år
-
FCF-udbetaling
-
Efterfølgende P/E
-
Fremtidig P/E
-
PEG
-
EPS-vekst
-
1 års afkast
-74.86%
3 års afkast
-
5 års afkast
-
10 års afkast
-
Senest opdateret: 2023-02-02

UDBYTTE

ADAG betaler ikke udbytte

VÆRDIANSÆTTELSE

Værdiansættelsesforhold

Loading...
Værdiansættelsesforhold-data
Efterfølgende P/E-
Pris til OCF-
Pris til FCF-
Pris til EBITDA-
EV i forhold til EBITDA-

Værdiansættelse (salg/bogført værdi)

Loading...
Værdiansættelse (salg/bogført værdi)-data
Pris til omsætning-
Pris til egenkapital0.71
EV i forhold til salg-

ØKONOMI

Pr. aktie

Loading...
Data pr. aktie
Aktuelt antal aktier43.42M
EPS (TTM)-
FCF pr. aktie (TTM)-

Resultatopgørelse

Loading...
Resultatopgørelse-data
Omsætning (TTM)0.00
Bruttofortjeneste (TTM)0.00
Driftsindkomst (TTM)0.00
Nettoindkomst (TTM)0.00
EPS (TTM)-
EPS (1 år frem)-2.14

Marginer

Loading...
Marginer-data
Bruttomargin (TTM)-
Driftsmargin (TTM)-
Fortjenstmargin (TTM)-

Balance

Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Balancedata
Kontanter168.04M
Nettotilgodehavender1.87M
Omsætningsaktiver i alt175.01M
Goodwill0.00
Immaterielle aktiver0.00
Ejendomme, anlæg og udstyr0.00
Sum aktiver178.56M
Kreditor4.67M
Kortfristet/nuværende langsigtet gæld17.00M
Summen af kortfristede forpligtelser56.46M
Sum gæld65.87M
Aktionærernes egenkapital112.68M
Materielle nettoaktiver112.68M

Likviditet

Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Kontantstrøm-data
Likviditet fra driften (TTM)0.00
Investeringsudgifter (TTM)0.00
Fri pengestrøm (TTM)0.00
Udbetalt udbytte (TTM)0.00

Finansiel indkomst

Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Data om finansiel indkomst
Egenkapitalafkast-
Afkast af aktiver-
Afkast af investeret kapital-
Kontant afkast af investeret kapital-

INFORMATION OM AKTIER

Aktiediagram

Loading...
Aktiekurs-data
Åbning2.00
Daglig høj2.00
Daglig lav1.83
Daglig volumen48K
Højeste gennem alle tider29.60
1 års analytiker estimat13.83
Beta-
EPS (TTM)-
Udbytte pr. aktie-
Ex-div dato-
Næste dato for resultatpræsentation30 Mar 2023

Nedsidepotensial

Loading...
Nedsidepotensial-data
ADAGS&P500
Nuværende prisfald fra top notering-93.78%-12.75%
Højeste prisfald-96.96%-56.47%
Højeste efterår dato31 Oct 20229 Mar 2009
Gennemsnitlig fald fra toppen-71.78%-11.49%
Gennemsnitlig tid til nyt højdepunkt250 days13 days
Maks. tid til nyt højdepunkt498 days1805 days
OPLYSNINGER OM VIRKSOMHEDEN
ADAG (Adagene Inc) company logo
Markedsværdi
79.90M
Markedsværdi kategori
Small-cap
Beskrivelse
Adagene Inc., a clinical stage biopharmaceutical company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase I clinical trial for the treatment of advanced metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody, which is in preclinical; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical stage for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a CD20xCD3 POWERbody, which is in preclinical stage for the treatment off-tumor toxicities. The company was incorporated in 2011 and is headquartered in Suzhou, China.
Personale
259
Investor relationer
-
SEC-indsendelser
Adm. direktør
Land
USA
By
Aktietype
-
CCC-status
-
Utbyttefrekvens
-
ARRANGEMENTER OG PRÆSENTATIONER
ArrangementerPræsentationer
Loading...
FORSTÅ FORRETNINGEN
Loading...
NYHEDER OM VIRKSOMHEDEN
Alle nyhederPressemeddelelser
- No dose-limiting toxicities observed when ADG126 combined up to 10 mg/kg with repeat cycles, highlighting compelling safety profile with SAFEbody precision masking technology - - Partial responses c...
9. januar 2023
SAN DIEGO and SUZHOU, China, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of antibody-based therapies, today announce...
5. januar 2023
SAN DIEGO and SUZHOU, China, Dec. 16, 2022 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of antibody-based therapies, today announce...
16. december 2022
SAN DIEGO and SUZHOU, China, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of antibody-based therapies, today announce...
21. november 2022
- Interim phase 1b/2 data report safety profile of ADG116 across dosing levels, with repeat dosing of more than four cycles both as monotherapy and in combination with anti-PD-1 therapy - - Results in...
10. november 2022
- NEObody technology platform enables dynamic targeting of a distinct epitope of CTLA-4 for enhanced safety and efficacy - - Data from phase 1b/2 studies in heavily pre-treated patients showcase diffe...
11. oktober 2022
- Best-in-class profile demonstrated with repeat dosing across dose levels - - Antitumor activity observed in cold tumors with steady accumulation of activated ADG126 - - On track in 2022 to report re...
10. september 2022
– Topline data for anti-CTLA-4 antibody, ADG116, shows compelling clinical safety and complete and partial responses as both a single agent and in combination with anti-PD-1 therapy; results to be pre...
30. august 2022
SAN DIEGO and SUZHOU, China, June 29, 2022 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today an...
29. juni 2022
Adagene Inc. ("Adagene") (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced the publication of data showing the potential best-in-c...
27. maj 2022
Næste side